Fact CheckerSign in

NCT06637462Recruiting

A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer

DISCRN in Rectal Cancer: DISseCting Response to Neoadjuvant Therapy in Rectal Cancer

Source: ClinicalTrials.gov · Last updated 2 Jun 2026

Brief summary (registry, in English)

The purpose of the study is to learn more about how the body responds to standard treatment (chemoradiation and chemotherapy). The study will use the results of testing down on participants' blook, tissue, and scans to learn more about how people with rectal cancer respond to chemoradiation and chemotherapy treatment and if it is useful for predicting whether a person's cancer get better, gets worse, or stats the same after treatment.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
60 (estimated)
First submitted
9 Oct 2024
Start date
9 Oct 2024
Primary completion date
9 Oct 2027
Lead sponsor
Memorial Sloan Kettering Cancer Center
NCT number
NCT06637462

What you commit to

  • Study type: Interventional
  • Planned participants: 60
  • From 9 Oct 2024 to the primary completion date, 9 Oct 2027
  • 6 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.
  • Patients with prior external beam radiation therapy to the pelvis or brachytherapy seed implantation of the prostate.

Other

  • Patients who are pregnant or breastfeeding.
  • Men or women not using effective contraception.
  • Patients with a contraindication to MR imaging.
  • Patients on blood thinners prohibiting endoluminal tumor biopsies.

Who the study is looking for

  • 18 years of age or older on day of signing informed consent.
  • Have a histologically confirmed diagnosis of invasive adenocarcinoma of the rectum with no known mismatch repair deficiency or Her2 amplification.
  • Eligible for and plan to initiate standard-of-care therapy with any of the following regimens:
    • Induction fluoropyrimidine (capecitabine \[preferred\] or 5-FU) based chemoradiation
    • With plan for consolidative CAPEOX, FOLFOX, or FOLIRINOX
  • Woman with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use an effective contraceptive method. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. Reliable contraception should be used from the time of screening and must be continued throughout the duration of treatment as per standard of care.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (6)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Coordinator of this site? Confirm its status
CommackUnited StatesRecruiting
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Coordinator of this site? Confirm its status
HarrisonUnited StatesRecruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Coordinator of this site? Confirm its status
MiddletownUnited StatesRecruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Coordinator of this site? Confirm its status
MontvaleUnited StatesRecruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Coordinator of this site? Confirm its status
New YorkUnited StatesRecruiting
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Coordinator of this site? Confirm its status
Rockville CentreUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.